Based on a report in The Indian Express, a Bengaluru company has become India’s first to get the international CARB-X grant to develop antibiotics to cure hospital-acquired diseases.
CARB-X is a public-private international company, that was set up in 2016 to concentrate on innovations to advance diagnosis and treatment of drug-resistant infections. Antibiotics resistance has become a worldwide crisis that threatens the management of infections, both in the community and in hospital practice.
An Indian company, Bangalore-based Bugworks Research, has got an initial fund of $ 2.6 million for its work on a new class of antibiotics to fight against ESKAPE. ESKAPE pathogens are considered the leading cause of hospital-born and hospital acquired infections throughout the world.
You can read more here (You will be redirected to a third-party website)